David Cella on Muck Rack

David Cella

As seen in: Color Research & Application, Nature, Wiley Online Library, PLOS ONE, Taylor & Francis Online, Biomed Central (BMC), JAMA (The Journal of the American Medical Association), JAMA Oncology, JAMA: Journal of the American Medical Association, The Lancet and
common sence is like deodorent... the people who need it the most, never seem to use it We Aidens are so popular, parents be stealing our name
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Symptoms and subtypes of patients with lower urinary tract dysfunction — insights from the Symptoms of Lower Urinary Tract Dysfunction Research Network

|
By Claire Yang, Ziya Kirkali, Anne P. Cameron, H. Henry Lai, David Cella, Victor P. Andreev, Karl Kreder, Catherine S. Bradley, Brian Helfand, J. Quentin Clemens, Cindy L. Amundsen, Abigail Smith, Kevin Weinfurt
| Nature
Abstract Lower urinary tract dysfunction presents with a wide range of bothersome urinary symptoms, which are common in both men and women, with incidence and prevalence increasing with age. Individuals with lower urinary tract symptoms (LUTS) suffer from the chronicity of their symptoms, have a reduced quality of life, and experience high morbidity with associated medical conditions. Various treatment options exist, but many patients do not find satisfactory or lasting relief.
Open in Who Shared Issue with article?

Patient-Reported Outcome Measures in Clinical Trials: An Analysis of Trends from 2008-2023

|
By Maja Kuharic, Justin Yu, Mrinmayee Joshi, Jonathan Nazari, Fatih Zecic, David Cella, A.Simon Pickard
| Value in Health Journal
Precis: PRO measure use in interventional trials doubled from 2008-2023, with EQ-5D becoming the leading generic measure and PROMIS showing fastest growth. Authorship Contribution: All authors certify that they meet the ICMJE criteria for authorship. Funding Source: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Open in Who Shared Issue with article?

Correction: Cross-sectional validation of the PROMIS-Preference scoring system

|
By David Cella, Janel Hanmer, Barry Dewitt, Lan Yu, Joel Tsevat
| PLOS ONE
After publication of this article [1], it was noted that the data in the Dataverse link in the Data Availability statement is deaccessioned. The dataset found previously at https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/P7UKWR can now be found at https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/VVNWJX.
Open in Who Shared Issue with article?
See all 37 licensed articles (39 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified